Connecting Research and Experts with Journalists

• share
• favorite_border

The U.S. Food and Drug Administration approved the use of Photofrin(r), a light activated drug used in Photodynamic Therapy, for treatment of patients with early-stage lung cancer.

• share
• favorite_border

Roswell Park Cancer Institute will host the first meeting of a Regional Cancer Center Consortium for Biological Therapy of Cancer, February 19-21, in honor of the Institute's Centennial.

• share
• favorite_border

The first report of the discovery of inhaled cellulosic and plastic fibers in human lung tissue has been published by researchers at Roswell Park Cancer Institute in the May, 1998 issue of Cancer Epidemiology, Biomarkers & Prevention. The fibers in the human lung may be bioresistant and biopersistent candidate agents contributing to the risk of lung cancer.

• share
• favorite_border

Lung cancer is the most common cause of cancer deaths in North America. Innovative technology at RPCI will enable physicians to detect premalignant and preinvasive neoplastic lesions in the lung and initiate appropriate curative treatments such as surgery, radiation therapy, chemotherapy or in many cases, photodynamic therapy using the photosensitzer, Photofrin.

• share
• favorite_border

There is no such thing as a "safe" cigarette, concludes Roswell Park Cancer Institute (RPCI) investigators, whose comprehensive analysis of one "safe cigarette" appears in today's issue of Cancer Epidemiology, Biomarkers & Prevention.

• share
• favorite_border

Fewer chemotherapy treatments, less intense side effects and fewer visits to the hospital are on the horizon for some pediatric patients. These are the results of an eight-year clinical trial in patients with Wilms' tumor, a cancer of the kidney most often seen in children, published in today's Journal of Clinical Oncology.

• share
• favorite_border

A Roswell Park Cancer Institute scientist and Axis Genetics plc., Cambridge, United Kingdom, will collaborate to advance the first edible plant vaccine to protect against hepatitis B virus infection.

• share
• favorite_border

A multi-institutional clinical study led by Roswell Park Cancer Institute has demonstrated the safety and effectiveness of a chemoimmunotherapy treatment for patients with non-Hodgkin's lymphoma. The overall response rate was 95% for patients who received treatment with a combination of Rituxan, a monoclonal antibody, and the systemic standard dose chemotherapy regimen used for this disease.

• share
• favorite_border

David C. Hohn, MD, President and CEO, Roswell Park Cancer Institute (RPCI), today announced the formation of the Roswell Park Cancer Institute Corporation (RPCIC) and the composition of the RPCIC Board of Directors under the direction of Board Chairman, Mr. Patrick P. Lee, Chairman and CEO of International Motion Control Inc.

• share
• favorite_border

Researchers from Roswell Park Cancer Institute (RPCI) are part of an international group studying the long-term health effects caused by the destruction of the nuclear power plant in Chernobyl, Ukraine, April 26, 1986, which exposed thousands to radiation and contaminated farmlands in the Ukraine and Belarus.